Postprandial hyperlipemia is associated with the development of cardiovascular disease. Orlistat is a pancreatic lipase inhibitor that reduces fat absorption from the diet by inhibition of hy-drolysis of triglycerides. Since the effect of orlis-tat on postprandial lipemia has not been fully elucidated, we studied the effect of orlistat on postprandial lipemia after a 50% oral fat chal-lenge test (OFCT). Materials and Methods: Twenty-seven healthy volunteers, aged 18-45 years old, with normal body mass index (BMI) and normal fasting lipid levels, were studied. The control group (n=15) was given the 50% OFCT while the study/orlistat group (n=12), was given 120 mg orlistat followed by intake of the 50% OFCT. Total cholesterol (TC), triglycerides (TG), high density lipoprotein (HDL) and low density lipoprotein (LDL) were determined at baseline and serially over a 6-hour period. Re-sults: In the control group, TC, TG and HDL peaked in the 4th hour. This lipid peaking was not observed in the orlistat group. Percentage change between baseline to the 4th hour values in the control vs. the study group were, respec-tively, as follows: TC = 65.80% vs. -1.60%; TG = 262.64% vs. 24.74%; and HDL = 205.26% vs. -1.43%. The mean postprandial levels for TC, TG and LDL were well within the normal fasting cut-offs of <6.20 mmol/L, <2.26 mmol/L, and < 4.14 mmol/L respectively throughout the entire 6-hour study period. Conclusion: Orlistat ab-olished the peaking of TC, TG, and HDL after a 50% OFCT. Nonetheless, lipid values were main-tained within normal fasting levels in the orlistat group.

"/> Postprandial hyperlipemia is associated with the development of cardiovascular disease. Orlistat is a pancreatic lipase inhibitor that reduces fat absorption from the diet by inhibition of hy-drolysis of triglycerides. Since the effect of orlis-tat on postprandial lipemia has not been fully elucidated, we studied the effect of orlistat on postprandial lipemia after a 50% oral fat chal-lenge test (OFCT). Materials and Methods: Twenty-seven healthy volunteers, aged 18-45 years old, with normal body mass index (BMI) and normal fasting lipid levels, were studied. The control group (n=15) was given the 50% OFCT while the study/orlistat group (n=12), was given 120 mg orlistat followed by intake of the 50% OFCT. Total cholesterol (TC), triglycerides (TG), high density lipoprotein (HDL) and low density lipoprotein (LDL) were determined at baseline and serially over a 6-hour period. Re-sults: In the control group, TC, TG and HDL peaked in the 4th hour. This lipid peaking was not observed in the orlistat group. Percentage change between baseline to the 4th hour values in the control vs. the study group were, respec-tively, as follows: TC = 65.80% vs. -1.60%; TG = 262.64% vs. 24.74%; and HDL = 205.26% vs. -1.43%. The mean postprandial levels for TC, TG and LDL were well within the normal fasting cut-offs of <6.20 mmol/L, <2.26 mmol/L, and < 4.14 mmol/L respectively throughout the entire 6-hour study period. Conclusion: Orlistat ab-olished the peaking of TC, TG, and HDL after a 50% OFCT. Nonetheless, lipid values were main-tained within normal fasting levels in the orlistat group.

"/>

Orlistat Abolishes Postprandial Lipid Peaking

AUTHORS

Z R Abejuela 1 , * , A G Macaballug 2 , J P Sumpio 3 , M B Zacarias 3 , L B Mercado 4

1 Sections of Endocrinology and Metabolism University Of Santo Tomas Hospital, [email protected], Philippines

2 Sections of Endocrinology and Metabolism University Of Santo Tomas Hospital, Philippines

3 Dietary Services, University Of Santo Tomas Hospital, Manila, Philippines

4 Cardiology,University Of Santo Tomas Hospital, Manila, *, Philippines

How to Cite: Abejuela Z, Macaballug A, Sumpio J, Zacarias M, Mercado L. Orlistat Abolishes Postprandial Lipid Peaking, Int J Endocrinol Metab. Online ahead of Print ; 7(3):179-186.

ARTICLE INFORMATION

International Journal of Endocrinology and Metabolism: 7 (3); 179-186
Article Type: Original Article
Received: November 15, 2008
Accepted: August 1, 2009
READ FULL TEXT

Abstract

Postprandial hyperlipemia is associated with the development of cardiovascular disease. Orlistat is a pancreatic lipase inhibitor that reduces fat absorption from the diet by inhibition of hy-drolysis of triglycerides. Since the effect of orlis-tat on postprandial lipemia has not been fully elucidated, we studied the effect of orlistat on postprandial lipemia after a 50% oral fat chal-lenge test (OFCT). Materials and Methods: Twenty-seven healthy volunteers, aged 18-45 years old, with normal body mass index (BMI) and normal fasting lipid levels, were studied. The control group (n=15) was given the 50% OFCT while the study/orlistat group (n=12), was given 120 mg orlistat followed by intake of the 50% OFCT. Total cholesterol (TC), triglycerides (TG), high density lipoprotein (HDL) and low density lipoprotein (LDL) were determined at baseline and serially over a 6-hour period. Re-sults: In the control group, TC, TG and HDL peaked in the 4th hour. This lipid peaking was not observed in the orlistat group. Percentage change between baseline to the 4th hour values in the control vs. the study group were, respec-tively, as follows: TC = 65.80% vs. -1.60%; TG = 262.64% vs. 24.74%; and HDL = 205.26% vs. -1.43%. The mean postprandial levels for TC, TG and LDL were well within the normal fasting cut-offs of <6.20 mmol/L, <2.26 mmol/L, and < 4.14 mmol/L respectively throughout the entire 6-hour study period. Conclusion: Orlistat ab-olished the peaking of TC, TG, and HDL after a 50% OFCT. Nonetheless, lipid values were main-tained within normal fasting levels in the orlistat group.

Full Text

Full text is available in PDF

© 0, International Journal of Endocrinology and Metabolism. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
COMMENTS

LEAVE A COMMENT HERE: